BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo 2019;33:1411-20. [PMID: 31471386 DOI: 10.21873/invivo.11618] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Bai XM, Yang W. Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 677-683 [DOI: 10.11569/wcjd.v29.i13.677] [Reference Citation Analysis]
2 Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hong J, Cao L, Xie H, Liu Y, Yu J, Zheng S. Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis. Hepatobiliary Surg Nutr 2021;10:623-30. [PMID: 34760966 DOI: 10.21037/hbsn.2020.03.15] [Reference Citation Analysis]
4 Rizzo A, Ricci AD, Frega G, Di Federico A, Brandi G. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Rev Gastroenterol Hepatol 2021;15:567-74. [PMID: 33787429 DOI: 10.1080/17474124.2021.1911646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int 2020;40:2008-20. [PMID: 32279446 DOI: 10.1111/liv.14462] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
6 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Reference Citation Analysis]
7 Monteiro AR, Conde RS, Basto R, Sclafani F, Deleporte A, Hendlisz A, Dal Lago L. Targeted agents in older patients with gastrointestinal cancers - An overview. J Geriatr Oncol 2021:S1879-4068(21)00161-2. [PMID: 34226158 DOI: 10.1016/j.jgo.2021.06.013] [Reference Citation Analysis]
8 Yang Y, Liao Y, Gui YP, Zhao L, Guo LB. GL-V9 reverses adriamycin resistance in hepatocellular carcinoma cells by affecting JNK2-related autophagy. Chin J Nat Med 2020;18:491-9. [PMID: 32616189 DOI: 10.1016/S1875-5364(20)30059-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ahlers CG, Trinh QH, Montenovo M. Hepatocellular Carcinoma in a 24-Year-Old Female with Beckwith-Wiedemann Syndrome: A Case Report and Review of the Literature. Case Rep Genet 2020;2020:8811296. [PMID: 33083068 DOI: 10.1155/2020/8811296] [Reference Citation Analysis]
10 Zhao Y, Sun Y, Yang J, Zhu Z, Jia X. WITHDRAWN: Circ_0000517 contributes to hepatocellular carcinoma progression by upregulating ARID4B via sponging miR-328-3p. Cell Signal 2021;:109950. [PMID: 33582185 DOI: 10.1016/j.cellsig.2021.109950] [Reference Citation Analysis]
11 Ren K, Yin X, Zhou B. Effects of surgery on survival of patients aged 75 years or older with Merkel cell carcinoma. Cancer Med 2022;11:128-38. [PMID: 34821054 DOI: 10.1002/cam4.4437] [Reference Citation Analysis]
12 Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, Fabbrocini A, Petrillo A, Daniele B. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel) 2021;14:233. [PMID: 33800217 DOI: 10.3390/ph14030233] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
14 Wu D, Zhang R, Zhan L. Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile. Clin Res Hepatol Gastroenterol 2021;46:101812. [PMID: 34597849 DOI: 10.1016/j.clinre.2021.101812] [Reference Citation Analysis]
15 Yan J, Man Z, Lu Q, Ma K. Long-Term Survival in Patients Receiving Combination Therapy with Resection and Radiofrequency Ablation for Multi-Focal Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B: A Retrospective Controlled Study. Cancer Manag Res 2020;12:2613-21. [PMID: 32368139 DOI: 10.2147/CMAR.S237635] [Reference Citation Analysis]
16 Huang Z, Gu Y, Zhang T, Wu S, Wang X, An C, Huang J. Nomograms to predict survival outcomes after microwave ablation in elderly patients (>65 years old) with early-stage hepatocellular carcinoma. Int J Hyperthermia 2020;37:808-18. [PMID: 32619374 DOI: 10.1080/02656736.2020.1785556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pang Y, Tan G, Yang X, Lin Y, Chen Y, Zhang J, Xie T, Zhou H, Fang J, Zhao Q, Ren X, Li J, Lyu J, Wang Z. Iron-sulphur cluster biogenesis factor LYRM4 is a novel prognostic biomarker associated with immune infiltrates in hepatocellular carcinoma. Cancer Cell Int 2021;21:463. [PMID: 34488769 DOI: 10.1186/s12935-021-02131-3] [Reference Citation Analysis]
18 Kim JM, Rhu J, Ha SY, Choi GS, Kwon CHD, Kim G, Joh JW. Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older. Ann Surg Treat Res 2021;101:257-65. [PMID: 34796141 DOI: 10.4174/astr.2021.101.5.257] [Reference Citation Analysis]